Published in Cancer Weekly, August 11th, 2009
"A randomized phase II trial was conducted in 40 patients with PSA progression. had PSA doubling times less than 10 months, with no overt evidence of disease. received either weekly subcutaneous injection (sc) of TG4010 10(8) pfu for 6 weeks, then one injection every 3 weeks or sc injection of TG4010 10(8) pfu every 3 weeks. The primary endpoint of a 50% decrease in PSA values from baseline was not observed....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.